Citation Impact
Citing Papers
Matrix Protein CCN1 Is Critical for Prostate Carcinoma Cell Proliferation and TRAIL-Induced Apoptosis
2009 Standout
Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib
2006
MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo
2010 Standout
Factors Associated With Severe Late Toxicity After Concurrent Chemoradiation for Locally Advanced Head and Neck Cancer: An RTOG Analysis
2008 Standout
Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells.
2003
ErbB Receptors: Directing Key Signaling Networks Throughout Life
2004
The Correlation Between Cytoplasmic Overexpression of Epidermal Growth Factor Receptor and Tumor Aggressiveness
2004
Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors
2005
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
2007 Standout
EGFR Antagonists in Cancer Treatment
2008 Standout
Perspectives on cancer therapy-induced mucosal injury
2004 Standout
Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective
2009 Standout
Radiation-induced lung injury
2003
ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy)
2009 Standout
Pulmonary fibrosis: pathogenesis, etiology and regulation
2009 Standout
Role of antioxidants in cancer therapy
2012
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
2014 Standout
Macrolides sensitize EGFR-TKI-induced non-apoptotic cell death via blocking autophagy flux in pancreatic cancer cell lines
2015 StandoutNobel
The molecular biology of head and neck cancer
2010 Standout
Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis
2004
Chemical radioprotection: A critical review of amifostine as a cytoprotector in radiotherapy
2003
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
2007 StandoutNature
Targeting apoptosis in cancer therapy
2020 Standout
Review: Ultraviolet radiation and skin cancer
2010
Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non–small-cell lung cancer
2003
Showering c-MET-dependent cancers with drugs
2008
Systematic review of agents for the management of gastrointestinal mucositis in cancer patients
2012
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
2020 Standout
The densely fluorinated nanospace of a porous coordination polymer composed of perfluorobutyl-functionalized ligands
2014 StandoutNobel
A practical approach to pulmonary risk assessment in the radiotherapy of lung cancer
2004
The TRAIL apoptotic pathway in cancer onset, progression and therapy
2008
Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies
2006 Standout
Randomized Trial of Amifostine in Locally Advanced Non–Small-Cell Lung Cancer Patients Receiving Chemotherapy and Hyperfractionated Radiation: Radiation Therapy Oncology Group Trial 98-01
2005
Randomized Double-Blind Trial of Combined Modality Treatment With or Without Amifostine in Unresectable Stage III Non–Small-Cell Lung Cancer
2003
ICRP PUBLICATION 118: ICRP Statement on Tissue Reactions and Early and Late Effects of Radiation in Normal Tissues and Organs — Threshold Doses for Tissue Reactions in a Radiation Protection Context
2012 Standout
Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer
2010
Molecular Mechanisms of Resistance to Therapies Targeting the Epidermal Growth Factor Receptor
2005
Oxygen Carriers (“Blood Substitutes”)Raison d'Etre, Chemistry, and Some PhysiologyBlut ist ein ganz besondrer Saft
2001
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
2014 Standout
Combination therapy in combating cancer
2017 Standout
Control of skin cancer by the circadian rhythm
2011 StandoutNobel
Amifostine: The First Selective-Target and Broad-Spectrum Radioprotector
2007
UV Radiation and the Skin
2013 Standout
Recent advancements in natural dye applications: a review
2013 Standout
Works of Roy Herbst being referenced
Knowledge, attitudes, and behaviors toward skin cancer in Maryland youths
2002
Erlotinib (Tarceva): An update on the clinical trial program
2003
Application of pharmacodynamic assays in a phase Ia trial of Apo2L/TRAIL in patients with advanced tumors
2007
PEG-hemoglobin: effects on tumor oxygenation and response to chemotherapy.
1997
Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: Preliminary results
2002
IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer
2002